Sectoral Asset Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Sectoral Asset Management’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-12,594	Closed	-$47K	–	69
2019 Q2	$47K	Hold	12,594	–	–	0.01%	89
2019 Q1	$51K	Hold	12,594	–	–	0.01%	105
2018 Q4	$46K	Hold	12,594	–	–	0.01%	101
2018 Q3	$108K	Buy	+12,594	New	+$126K	0.01%	159
2017 Q2	–	Sell	-67,200	Closed	-$1.4M	–	65
2017 Q1	$1.4M	Buy	+67,200	New	+$1.05M	0.16%	54

Other funds holding CRVS

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Sectoral Asset Management's CRVS Position: Q3 2019 in Review

Sectoral Asset Management sold out of Corvus Pharmaceuticals (CRVS) in Q3 2019, closing a stake of 12,594 shares — an estimated $47K sold.

Sectoral Asset Management first reported a position in CRVS in Q1 2017 and held it in 5 quarters. The position peaked at $1.4M in Q1 2017. 35 funds tracked by Wall St. Rank hold CRVS as of Q3 2019.

Sectoral Asset Management reported no remaining Corvus Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Sectoral Asset Management sold 12,594 Corvus Pharmaceuticals shares in Q3 2019, an estimated $47K.
Sectoral Asset Management first reported a position in Corvus Pharmaceuticals in Q1 2017 and held it in 5 quarters.
Sectoral Asset Management's Corvus Pharmaceuticals position peaked at $1.4M in Q1 2017.
35 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q3 2019.

Based on Sectoral Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.